Acta Neurochirurgica, 2025 · DOI: https://doi.org/10.1007/s00701-025-06443-5 · Published: January 24, 2025
Methylprednisolone (MP) is a synthetic glucocorticoid medication that shares a similar chemical structure with the endogenously secreted glucocorticoid cortisol. Early research reports suggested that high-dose glucocorticoids may alleviate the inflammatory response following SCI and possibly promote neural recovery. Methylprednisolone application in Spinal Cord Injury (SCI) from 1975 to 2023 was examined using Web of Science and CiteSpace software.
Future studies will primarily focus on guidelines, clinical practices, and global standards.
Addresses the efficacy of the existing methylprednisolone therapy and determines whether low or high doses are more effective.
Focus on the development of novel drug delivery systems to reduce the systemic side effects of methylprednisolone.